<p>BACKGROUND: Sensitive skin and
rosacea are skin conditions, which may affect the quality of life of the patients considerably. In vitro and in vivo data indicated that the combination of trans-t-butylcyclohexanol and
licochalcone A is an effective combination for alleviating the increased sensitivity of
rosacea subtype I.</p> <p>OBJECTIVE: Objective of this open dermocosmetic study was to investigate the efficacy and tolerability of a
skin care product containing the anti-inflammatory
licochalcone A and the TRPV1 antagonist trans-t-butylcyclohexanol in subjects with sensitive skin prone to redness and
rosacea.</p> <p>METHODS: 1221 subjects with sensitive skin and
rosacea stage 0-II applied the test product twice daily for 4 weeks. Clinical assessment of sensitive skin and
rosacea symptoms were performed at baseline and after 4 weeks. Additionally, at treatment end the test subjects filled a self-assessment questionnaire.</p> <p>RESULTS: After 4 weeks of application, both, clinical and subjective assessment have shown improvement of all symptoms of sensitive skin and
rosacea in a significant number of subjects (P less than 0.001). The test product was efficacious and very well tolerated also when used in conjunction with pharmacological treatments of the skin condition under scrutiny.</p> <p>Conclusions: The study confirmed the good tolerability and efficacy of the
skin care product in the management of sensitive skin prone to redness and
rosacea when used alone or in combination with other
therapies.</p> <p><em>J Drugs Dermatol. 2017;16(6):605-611.</em></p>.